DG
CRL icon

Daventry Group’s Charles River Laboratories CRL Stock Holding History

Daventry Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-106,823
Closed -$21M – 10
2024
Q3 		$21M Sell
106,823
-12,872
-11% -$2.68M 8.37% 6
2024
Q2 		$24.7M Buy
119,695
+4,033
+3% +$914K 11.04% 4
2024
Q1 		$31.3M Buy
115,662
+4,500
+4% +$1.07M 12.53% 3
2023
Q4 		$26.3M Buy
111,162
+32,554
+41% +$6.4M 11.28% 5
2023
Q3 		$15.4M Buy
78,608
+6,985
+10% +$1.43M 9.82% 6
2023
Q2 		$15.1M Buy
71,623
+8,500
+13% +$1.69M 11.15% 7
2023
Q1 		$12.7M Buy
+63,123
New +$14.3M 8.91% 7

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Daventry Group's CRL Position: Q4 2024 in Review

Daventry Group sold out of Charles River Laboratories (CRL) in Q4 2024, closing a stake of 106,823 shares — an estimated $21M sold.

Daventry Group first reported a position in CRL in Q1 2023 and held it in 7 quarters. The position peaked at $31.3M in Q1 2024. 637 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

  • Daventry Group reported no remaining Charles River Laboratories position as of Q4 2024 after selling out during the quarter.
  • Daventry Group sold 106,823 Charles River Laboratories shares in Q4 2024, an estimated $21M.
  • Daventry Group first reported a position in Charles River Laboratories in Q1 2023 and held it in 7 quarters.
  • Daventry Group's Charles River Laboratories position peaked at $31.3M in Q1 2024.
  • 637 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Daventry Group's 13F filing for Q4 2024, filed 14 Feb 2025.